LYNX Trademark

Trademark Overview

On Friday, December 10, 2021, a trademark application was filed for LYNX with the United States Patent and Trademark Office. The USPTO has given the LYNX trademark a serial number of 97166586. The federal status of this trademark filing is REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED as of Wednesday, February 4, 2026. This trademark is owned by Lyndra Therapeutics, Inc.. The LYNX trademark is filed in the Pharmaceutical Products category with the following description:

Drug delivery systems in the form of oral capsules that provide controlled release of the active ingredients for a wide variety of therapeutic agents

General Information

Serial Number97166586
Word MarkLYNX
Filing DateFriday, December 10, 2021
Status654 - REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED
Status DateWednesday, February 4, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesDrug delivery systems in the form of oral capsules that provide controlled release of the active ingredients for a wide variety of therapeutic agents

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameISP ACQUISITION COMPANY, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressLEXINGTON, MA 02421
Party NameLyndra Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events

Event DateEvent Description
Tuesday, December 14, 2021NEW APPLICATION ENTERED
Wednesday, December 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 12, 2022ASSIGNED TO EXAMINER
Wednesday, May 18, 2022NON-FINAL ACTION WRITTEN
Wednesday, May 18, 2022NON-FINAL ACTION E-MAILED
Wednesday, May 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 13, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 13, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 13, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, November 13, 2022SUSPENSION LETTER WRITTEN
Sunday, November 13, 2022LETTER OF SUSPENSION E-MAILED
Sunday, November 13, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, May 19, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, January 3, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 3, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, January 3, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 3, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, January 8, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, January 2, 2025REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, February 19, 2025ASSIGNED TO EXAMINER
Friday, March 7, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, March 25, 2025ASSIGNED TO LIE
Tuesday, March 25, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 25, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 14, 2025SUSPENSION LETTER WRITTEN
Monday, April 14, 2025LETTER OF SUSPENSION E-MAILED
Monday, April 14, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, October 15, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, February 4, 2026REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, February 18, 2026AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Related Keywords

lynx ingredients active wide variety agents therapeutic release controlled systems delivery